Geburtshilfe Und Frauenheilkunde最新文献

{"title":"Oral Misoprostol +/- Double-Balloon Catheter Versus Vaginal Insertion of Dinoprostone for Induction of Labour at Full-Term.","authors":"Magdalena Annemarie Stöger, Stefan Hinterberger, Sven Kehl, Lukas Kristl, Lucia Gerhold, Lena Gruber, Isabel Krauss, Magdalena Rosenkranz, Anna Sellner, Karin Lagger, Christina Kulle, Albrecht Gebhardt, Johannes Lermann","doi":"10.1055/a-2852-3671","DOIUrl":"10.1055/a-2852-3671","url":null,"abstract":"<p><strong>Objective: </strong>Following the approval of an oral misoprostol preparation for labour induction in 2020, the previous procedure using a vaginal dinoprostone insert was replaced in Klagenfurt by oral misoprostol, with or without a double-balloon catheter (CRB - Cervical Ripening Balloon). The aim of this study was to compare the two methods in terms of effectiveness, safety and cost.</p><p><strong>Materials and methods: </strong>In a retrospective analysis, births from 37w+0d of gestation between September 2021 and August 2023 (misoprostol with or without CRB) were compared with the period from September 2018 to August 2020 (dinoprostone). The primary endpoint was the caesarean section rate. Secondary endpoints included perinatal outcome, duration of induction, complications, length of hospital stay, frequency of cardiotocography (CTG) monitoring and costs.</p><p><strong>Results: </strong>A total of 1011 cases were analysed in this study. Overall, the caesarean section rate did not differ significantly (26.8% in 2018-2020 vs. 23.9% in 2021-2023, p = 0.31). However, in the subgroup of first-time mothers without ruptured membranes, there was a significant reduction in the caesarean section rate in favour of CRB + misoprostol (45.3% vs. 34.4%, p = 0.02). Perinatal outcomes, complications and length of hospital stay were comparable. The duration of induction was significantly longer with CRB + misoprostol (18.2 hours vs. 25.5 hours, p < 0.01). With the sequential approach, more CTG checks were carried out (5.6 vs. 6.6, p < 0.01). The sequential regimen of CRB and misoprostol was, on average, € 9 more expensive per patient than induction using the dinoprostone vaginal insert alone.</p><p><strong>Conclusion: </strong>The combination of CRB and misoprostol is a safe and effective method of inducing labour. Despite a longer induction duration, the length of inpatient stay remains unchanged. In first-time mothers without rupture of membranes, it results in fewer caesarean sections compared with dinoprostone vaginal insert.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 6","pages":"563-570"},"PeriodicalIF":2.6,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Latest on Intrahepatic Cholestasis of Pregnancy - Update 2026.","authors":"Stanisƚaw Jurk, Andreas Kremer, Ekkehard Schleussner","doi":"10.1055/a-2845-6610","DOIUrl":"10.1055/a-2845-6610","url":null,"abstract":"<p><p>Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder specific to pregnancy. The condition is characterised by raised serum bile acids and aminotransferases and typically presents with pruritus as its defining symptom. Ursodeoxycholic acid remains the first line therapeutic option. Clinical management - including decisions regarding the timing of delivery - is guided principally by serum bile acid concentrations, with the aim of reducing perinatal complications. This review offers a clear and integrated overview of current diagnostic criteria, management strategies, and the evidence underpinning contemporary therapeutic recommendations.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 6","pages":"528-537"},"PeriodicalIF":2.6,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.","authors":"Beyhan Ataseven, Marco Battista, Matthias W Beckmann, Sara Brucker, Dominik Denschlag, Michael Eichbaum, Tanja Fehm, Markus Fleisch, Gerhard Gebauer, Peter Hillemanns, Lars Christian Horn, Atanas Ignatov, Ruediger Klapdor, Simone Marnitz-Schulz, Julia Radosa, Christoph Scholz, Dirk Vordermark, Clemens Tempfer","doi":"10.1055/a-2833-6208","DOIUrl":"10.1055/a-2833-6208","url":null,"abstract":"<p><p>The ESGO-ESTRO-ESP guideline 2025 integrates the molecular classification into prognostic risk stratification and therapeutic decisions for patients with endometrial cancer (EC). In particular, a refined stratification of the molecular subgroup No-Specific-Molecular-Profile (NSMP) has been recently introduced to better reflect its pronounced prognostic heterogeneity. Retrospective analyses by Jamieson et al. and Vermij et al. demonstrate that histological tumor grade and immunohistochemical estrogen receptor expression represent independent prognostic factors within the NSMP subgroup, allowing for the identification of a large subgroup with an excellent prognosis and a small subgroup with a poor prognosis. Additional exploratory post hoc analyses suggest a potential differential benefit of adjuvant chemotherapy in ER-negative NSMP EC. However, these observations remain hypothesis-generating and lack prospective validation. In addition, the exact cut-off for ER-positivity remains unclear. The ESGO guideline defines prognostic risk groups according to the estimated 5-year risk of recurrence and derives recommendations for adjuvant therapy accordingly. Key randomized trials, including PORTEC-1, PORTEC-2, PORTEC-3, GOG-249 and GOG-258, are incorporated alongside molecular subgroups, whose biological characteristics increasingly inform treatment intensity. In contrast, the German S3 guideline adopts a more conservative methodological approach, incorporating molecular markers primarily as supportive information, particularly in the absence of prospective evidence guiding specific therapeutic decisions. With respect to surgical management in early-stage disease (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] I-II), both guidelines show substantial agreement, especially regarding the preference for minimally invasive surgery and the avoidance of unnecessary radicality. Differences mainly relate to the indication for sentinel lymph node staging. This statement aims to provide a balanced contextualization of these conceptual differences and to support an informed discussion of current international developments.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 5","pages":"443-452"},"PeriodicalIF":2.6,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/082, May 2025).","authors":"Laura Lotz, Sabine Kliesch, Dunja Baston-Buest, Andreas Schüring, Magdalena Balcerek, Brigitta Bartsch, René Baumann, Matthias Beckmann, Karolin Behringer, Anja Borgmann-Staudt, Bettina Böttcher, Stefanie Corradini, Wolfgang Cremer, Andreas Dinkel, Tamara Diesch-Furlanetto, Stefanie Frenz, Ariane Germeyer, Maren Goeckenjan, Vera Hepp, Franc Hetzer, Andrea Jarisch, Heribert Kentenich, Ulrich A Knuth, Matthias Korell, Frank-Michael Köhn, Jana Bender-Liebenthron, Katja Lindel, Gloria Sarah Leszinski, Michael Lux, Julia Meißner, Oliver Micke, Alexander Müller, Frank Nawroth, Verena Nordhoff, Patricia Oppelt, Nicole Reisch, Elisabeth Reiser, Felix Reschke, Andreas Rink, Alexander Sahi, Nicole Sänger, Armin Soave, Schwab Roxana, Christian Sigg, Meike Sikora, Sascha Tauchert, Petra Thorn, Tobias Weberschock, Pauline Wimberger, Tewes Wischmann, Rachel Würstlein, Michael von Wolff, Ralf Dittrich","doi":"10.1055/a-2811-6101","DOIUrl":"10.1055/a-2811-6101","url":null,"abstract":"<p><p><b>Goal</b> The aim of this official guideline, which was coordinated by the German Society of Gynaecology and Obstetrics (DGGG) together with the German Society of Urology (DGU) and the German Society of Reproductive Medicine (DGRM), is to provide consensus-based recommendations for counselling and the use of fertility preservation measures in prepuscent girls and boys and for patients of reproductive age by evaluating the relevant literature. <b>Methods</b> This S2k guideline was developed by a structured consensus of representative members of various professional associations on behalf of the guideline commission of the DGGG, DGU and DGRM. <b>Recommendations</b> Recommendations for counselling and the use of fertility-preserving measures in patients are presented, taking into account their life circumstances, the planned oncological therapy and the individual risk profile, as well as the procedure for selected tumour entities.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 4","pages":"333-375"},"PeriodicalIF":2.6,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147767767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus on the Management of Inavolisib Side Effects. A Survey on Defined Side Effects, the Assumed Pathomechanism, Preventative and/or Therapeutic Measures Including the Integration of Additional Health Care Professionals - a Consensus Paper.","authors":"Carlo Fremd, Michaela Müller-Rösel, Tjoung-Won Park-Simon, Mattea Reinisch, Iris Scheffen, Manfred Welslau","doi":"10.1055/a-2821-5278","DOIUrl":"10.1055/a-2821-5278","url":null,"abstract":"<p><p>This consensus paper depicts prevention, identification, treatment, and the involvement of relevant medical specialists and other health care professionals in the management of defined side effects of the new selective oral PI3K inhibitor inavolisib. All topics were discussed and agreed upon between experts in oncology, gynecology, and diabetology from both clinical and private practice. In addition to a brief summary of the assumed pathomechanism of each selected side effect, the management of the defined adverse effects is described, based on respective severity and according to the summary of product characteristics (SmPC). These details are supplemented by the expertise and experience of the participating experts regarding possible preventative and supportive therapeutic measures, special precautions, and practical recommendations for daily clinical practice and patient management.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 5","pages":"433-442"},"PeriodicalIF":2.6,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual Distress Scale: Translation, Psychometric Validation, and Reference Values for Cisgender Women and Men in a Representative Population-based Sample in Germany.","authors":"Selina M Kronthaler, Iron J Hahn, Daniel Schulze, Maria M Karsten, Jens-Uwe Blohmer, Tatjana Tissen-Diabaté, Klaus M Beier, Laura Hatzler","doi":"10.1055/a-2786-2315","DOIUrl":"10.1055/a-2786-2315","url":null,"abstract":"<p><strong>Introduction: </strong>Sexual dysfunction is common but often remains undetected in gynecological care. Validated instruments can support accurate and efficient diagnosis, especially under time constraints and limited patient contact. The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) is an internationally validated instrument to assess sexual distress, the core diagnostic criterion for sexual dysfunction according to ICD-11. This study aimed to i) validate the factor structure of the German FSDS-DAO questionnaire, ii) examine its applicability in cisgender women and men, and iii) determine a clinically relevant cutoff score.</p><p><strong>Methods: </strong>The German version was developed using a standardized translation process and extended by a 16th item assessing distress due to pain during sexual activity. Validation was based on a representative German sample from a population survey on persons seeking help for sexual dysfunction (N = 4023). Cisgender women and men were matched using propensity scores based on sociodemographic characteristics. Confirmatory factor analysis and measurement invariance testing were conducted in the matched sample (N = 2829). A ROC analysis using an ICD-11 screening tool was performed in the full sample (N = 4023) to determine a clinically relevant cutoff.</p><p><strong>Results: </strong>The proposed factor structure was confirmed. Partial strict measurement invariance between women and men was observed, with one item showing group-specific properties. Overall, men reported slightly higher sexual distress (d = 0.13). A clinically relevant cutoff of 16 (AUC = 0.89) was identified with high diagnostic accuracy.</p><p><strong>Conclusion: </strong>With 16 items and a validated cutoff score of 16, the German version of the FSDS-DAO represents a practical screening instrument for use in the care of both women and men.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 7","pages":"638-648"},"PeriodicalIF":2.6,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC) on the Diagnostic Algorithm for the New Cervical Cancer Screening - Persistent HPV Infections and Squamous Cell Lesions: Evaluation of over 10000 Patients.","authors":"Melanie Henes, Ellen Mann, Christine Hirchenhain, Alexander Kentner, Christina Selgrad, Monika Hampl, Mignon-Denise Keyver-Paik, Jens Quaas, Julia Gallwas, Christopher Koßagk, Martina Helbig, Paul Gaß, Farnaz Jakubek, Maximilian Klar, Leon Henes, Volkmar Küppers","doi":"10.1055/a-2800-5139","DOIUrl":"10.1055/a-2800-5139","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer screening in Germany was newly regulated as of January 1, 2020. Since then, an organized cancer screening guideline (oKFE-RL) for cervical cancer screening has been effective. From the age of 20, a cytological smear is taken once a year and from the age of 35 a co-test is carried out every three years. In the event of abnormalities, an algorithm regulates the procedure. This algorithm states that even so-called low-risk groups should have a diagnostic colposcopy at an early stage. This approach has been widely discussed and continues to serve as the basis of this registry study.</p><p><strong>Methods: </strong>All patients who presented for a diagnostic colposcopy to the respective participating centers were included after consent. The focus was on the detection rate of CIN 3+ in diagnoses related to squamous cell changes and persistent HPV infection. The current data were compared with previous results to obtain information about the development of the new screening program.</p><p><strong>Results: </strong>A total of 12311 patients were included. The referral diagnosis was normal cytology and persistent HPV infection in 30.7%, normal cytology but positive case history and persistent HPV infection in 2.6%, and ASC-US in 11.0%. 7.7% had a cytological diagnosis of ASC-H and 17.6% had LSIL. 16.3% had HSIL (moderate dysplasia), 9.2% had HSIL (severe dysplasia) and 0.3% had HSIL with features suspicious for invasion. Cytology-diagnosed squamous cell carcinoma was found 0.2%. CIN 3+ was found in 63.3% of cases with HSIL (severe dysplasia). 27.4% of the HSIL group (moderate dysplasia) were diagnosed as CIN 3+ and 27.6% of the ASC-H group as CIN 3+ but with a relatively high percentage of cervical carcinomas (n = 7). CIN 3+ was identified in 10.7% of the LSIL group and in 10.8% of the ASC-US group. In the groups with persistent HPV infection/normal cytology (with or without a positive case history), 7.1/6.3% were diagnosed as CIN 3+ and 12.8% of HPV-negative patients as CIN 3+. When groups were differentiated according to age into \"below the age of 35\" and \"35 years and above\", only the younger group of HPV-negative patients had a statistically significantly higher rate of CIN 3+.</p><p><strong>Discussion: </strong>Using these data, we were able to show that, with the exception of the group with persistent HPV infection/normal cytology (without or with a positive case history), the target lesion CIN 3+ was identified in over 10% of cases. We suggest that a reevaluation to take high-risk HPV types into consideration should be carried out as some HPV types are associated with a significantly higher risk of developing cervical cancer and its precursors than other types. It is too early to say whether the new screening program will reduce the incidence and mortality of cervical cancer; this will need to be checked in further evaluations.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 4","pages":"382-394"},"PeriodicalIF":2.6,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147767765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical Dysplasia Diagnosed in Pregnancy - A Pre- and Postpartum Analysis.","authors":"Carsten Hagenbeck, Martina Helbig, Luisa Brandi, Jan-Philipp Cieslik, Nadine Scholten, Tanja Fehm, Monika Hampl","doi":"10.1055/a-2823-0518","DOIUrl":"10.1055/a-2823-0518","url":null,"abstract":"<p><strong>Background/purpose: </strong>Cervical lesion regression and persistence rates are notably high. This study aims to analyse postpartum changes in cervical dysplasia diagnosed during pregnancy. Furthermore, the impact of age, tobacco use, and mode of delivery on cervical findings was assessed as the existing data is inconclusive.</p><p><strong>Methods: </strong>This retrospective analysis included pregnant women diagnosed with cervical dysplasia, with complete pre- and postpartum colposcopy, cytology, and histological findings, along with HPV status. Postpartum rates of regression, persistence, and progression were determined and the influence of age, tobacco use, and mode of delivery on cervical preneoplastic lesions was analysed using ordered logistic regression.</p><p><strong>Results: </strong>The study included 102 patients treated between 2010 and 2015 with complete pre- and postpartum cytology and/or biopsy data. Postpartum evaluation showed a regression rate of 45.1%, persistence in 52%, and progression in 2.9%. No significant influence on these rates was observed for age (p = 0.255), tobacco use (p = 0.310), or mode of delivery (p = 0.217).</p><p><strong>Conclusion: </strong>Our findings support the recommended conservative approach of managing cervical lesions during pregnancy which advocates for continuation of the pregnancy with regular monitoring and postpartum surgery if necessary. If invasive cancer can be excluded, the mode of delivery should be based on obstetric criteria, irrespective of cervical findings.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 4","pages":"395-402"},"PeriodicalIF":2.6,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147767801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations.","authors":"Michael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, Carsten Denkert, Peter A Fasching, Renate Haidinger, Nadia Harbeck, Wolfgang Janni, David Krug, Sibylle Loibl, Diana Lüftner, Laura Michel, Eva Schumacher-Wulf, Christine Solbach, Rachel Würstlein, Jens Huober, Nina Ditsch","doi":"10.1055/a-2832-0168","DOIUrl":"https://doi.org/10.1055/a-2832-0168","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1055/a-2612-3790.].</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 3","pages":"e1"},"PeriodicalIF":1.9,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12981963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for the Care and Support of Women Affected by Sexual Violence. Guideline of the DGGG (S1-Level, AWMF Registry No. 015/097, December 2025, Version 1.0).","authors":"Matthias David, Nicole Balint, Lina Fryszer, Tanja Germerott, Christine Hirchenhain, Paulo Sokoll, Anne Tank, Axel Valet, Angela Wagner, Cleo Walz, Nadine Wilke-Schalhorst","doi":"10.1055/a-2797-1610","DOIUrl":"10.1055/a-2797-1610","url":null,"abstract":"<p><p><b>Objective</b> This guideline aims to improve and standardize medical care, support, and evidence collection for female victims of sexual violence in Germany. <b>Method</b> In accordance with the requirements for S1 guidelines, the contents were formally discussed and agreed upon in numerous online meetings by a representative interdisciplinary group of experts well versed in the guideline topic. The German Society for Gynecology and Obstetrics (DGGG) led the discussion. <b>Recommendations</b> Empathy, experience, and expertise, as well as respect and objectivity on the part of the medical personnel involved, are crucial for the care of women after sexual violence. The guideline provides 130 recommendations for the care and examination of women affected by sexual violence, including requirements for examination, the collection of evidence and documentation of injuries, testing for sexually transmitted infections, post-exposure prophylaxis and infectious disease follow-up examinations, as well as aspects of psychological and psychosocial care and psychological aftercare.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"86 7","pages":"597-629"},"PeriodicalIF":2.6,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}